Personalis
Kedar Hastak has a diverse work experience in the field of application science and cancer research. Kedar started their career as a Doctoral Thesis student at Case Western Reserve University, where they focused on studying the cancer chemopreventative effects of green tea polyphenol EGCG on prostate cancer and the molecular mechanism of cancer stasis by EGCG.
After completing their doctoral thesis, Kedar joined Cleveland Clinic as a Post Doctoral Fellow, where they worked on establishing the mechanism of S phase arrest and DNA damage caused by the pyrimidine nucleotide pathway antagonist PALA.
In 2006, Kedar joined Stanford University School of Medicine as a Research Fellow and later became an Instructor. During their time there, they led an ongoing study assessing the radiosensitizing effects of PARP inhibitors in pancreatic and lung cancers using in vitro genetic biomarkers and mouse xenograft models. Kedar also successfully executed an investigational study focused on the use of small molecule PARP inhibitors in combinatorial therapy against triple-negative breast cancers.
From 2012 to 2018, Kedar worked as an Instructor at UC Berkeley, where they taught a post-baccalaureate course in Human Cancer Biology.
In 2018, Kedar joined Personalis, Inc. as an Application Scientist. Kedar started as an Application Scientist and worked their way up to Senior Application Scientist, Manager, and currently serves as the Associate Director of Application Scientist.
Overall, Kedar Hastak has extensive experience in cancer research, application science, and teaching.
Kedar Hastak holds a Ph.D in Cancer Biology/Molecular Biology from Case Western Reserve University School of Medicine. Kedar also completed a Master of Science (MSc) in Chemopreventive Oncology and a Bachelor of Science (BSc) in Microbiology from the University of Mumbai.
This person is not in any teams
Personalis
4 followers
Personalis is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the VA Million Veteran Program (MVP). In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA’88-certified and CAP-accredited.